论文部分内容阅读
奈必洛尔(nebivolol,Neb)是第三代β肾上腺素能受体阻滞剂(β受体阻滞剂),它不同于其他β受体阻滞剂:它具有强的β1受体阻滞、一氧化氮(NO)介导的血管扩张以及逆转内皮功能异常的作用。在欧洲Neb已用于治疗原发性高血压和年龄≥70岁的稳定型轻中度慢性心力衰竭(CHF)。在Neb的药效学和药动学方面,已有相关实验证明:Neb能有效地降低血压,而且能有效地降低中老年CHF的死亡率和住院率。文中主要从Neb的药效学、药动学及相关实验研究方面,阐明Neb在治疗原发性高血压和中老年CHF的进展情况以及展望其在国内的临床应用。
Nebivolol (Neb) is the third generation beta adrenergic receptor blocker (beta blocker), which is different from other beta blockers: it has a strong beta 1 receptor resistance Hysteresis, nitric oxide (NO) -mediated vasodilatation and reversal of endothelial dysfunction. Neb has been used in Europe for the treatment of essential hypertension and stable mild-to-moderate chronic heart failure (CHF). In Neb’s pharmacodynamics and pharmacokinetics, there have been relevant experiments have shown that: Neb can effectively lower blood pressure, but can effectively reduce the mortality and hospitalization rate in elderly CHF. This article mainly from the Neb’s pharmacodynamics, pharmacokinetics and related experimental studies, to clarify the Neb in the treatment of essential hypertension and the progress of elderly CHF and its clinical application in the country.